<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201302174251N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-05-03</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effect of corticosteroid injections and platelet rich plasma on the treatment of shoulder tendinopathy</public_title>
      <acronym>PRP</acronym>
      <scientific_title>Comparative study of corticosteroid injections and platelet rich plasma in the treatment of patients with shoulder tendinopathy  compare sonographic findings</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2013-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>56</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/4514</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly divided into two groups based on random number table after confirming the diagnosis with MRI and referring to the sports medicine department, Blinding description: The platelet rich plasma group is injected one time. In this group, 35 ml of venous blood was taken and by the Selex centrifuge under the RCF protocol, the blood sample is separated from rich plasma platelet by 1700 and 3200 rpm.  Plasma rich platelets are separated after adding calcium gluconate 10% cc platelet concentrate obtained. The injection is performed by a sports medicine specialist in the form of intraarticular with an angle of 30-45 degrees from the posterolateral.
And if there is a partial rupture in tendon, 3 cc PRP injection is performed under ultrasound guidance at the tendon rupture site.
One week after the injection, the patient is visited, examined, given the necessary advice and also exercise prescription. Exercise is divided to scapula rehabilitation and shoulder muscles training. 
After one and three months, repeated examinations, including pain, function, Completion of WORC, DASH questionnaire and ultrasound changes was achieved , and a comparison between the patient's clinical and Para clinical symptoms within these periods was performed.
 The injection for corticosteroid group, however, is applied Methylprednisolone 40 mg once. For patients, one cc of Depomedrol and one cc of 2% lidocaine solution are injected into the intra articular joint in the same PRP manner. In this group, due to the blindness of the study, blood sampling of the patient is performed before corticosteroid injection.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Shoulder Tendinopathy.</hc_freetext>
      <i_freetext>Intervention 1: The platelet rich plasma group is injected twice within a month. In this group, 20 ml of venous blood was taken by centrifuges Selex protocol RCF, blood samples from the men with the 1800 and 2000 cycles and women with 1600 and 2000 cycle. Plasma rich platelets are separated after adding calcium gluconate 10% cc platelet concentrate obtained. Under ultrasound Guide, in collaboration with a radiologist and a sports medicine specialist in the area of sub-45 degree lateral Acromion is injected (based on Sonographic Guide). Assessment of clinical sing such as pain (based on VAS measurement), shoulder range of motion and its function is occurred. Moreover, musculoskeletal sonography is applied by two clinician experts. These (findings are) recorded and compared. Intervention 2: The injection for corticosteroid group, however, is applied MethylPrednisolone 40 mg  once or twice within a month based on the Rheumatologist decision.&#13;
At the baseline, after four weeks and also eight weeks after intervention, all the studies including pain, range of motion, function, and Sonographic findings changes are evaluated and compared with the data which is recorded before intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After deidentifing  participants, sharing data related to pain, ROM, function and thickness of tendon will be happened

When:
starting 6 months after publication

To whom:
Researchers and people working in Academic institution

Conditions:
To applied in research or manuscript

Where to obtain:
Personal email, Mobile phone , research gate

How to obtain:
3 months after applying, the document will send through email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Haleh Dadgostar MD</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahr Ara street Sattar khan street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2446</telephone>
        <email>hldadgostar@gmail.com</email>
        <affiliation>sports medicine department Rasoul e Akram hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Haleh Dadgostar MD</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahr Ara street Sattar khan street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6435 2446</telephone>
        <email>hldadgostar@gmail.com</email>
        <affiliation>Sports Medicine Research Center Tehran University of Medical Sciences Tehran Iran</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Shoulder pain that lasts for more than 3 months
limited shoulder range of motion
Absence of radicular pain
Inflammatory disorders such as rheumatoid arthritis
Fibromyalgia
lack of complete rotator cuff tear
The ligament laxity
Non-corticosteroid injections in the past three months</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unwillingness of the patient to continue treatment
shoulder joint surgery
The presence of other disorders that limit joint motion such as frozen shoulder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M75.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>rotator cuff syndrome  rotator cuff or supraspinatous tear or rupture (complete ) ( incomplete ) not specified as traumatic</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The platelet rich plasma group is injected twice within a month. In this group, 20 ml of venous blood was taken by centrifuges Selex protocol RCF, blood samples from the men with the 1800 and 2000 cycles and women with 1600 and 2000 cycle. Plasma rich platelets are separated after adding calcium gluconate 10% cc platelet concentrate obtained. Under ultrasound Guide, in collaboration with a radiologist and a sports medicine specialist in the area of sub-45 degree lateral Acromion is injected (based on Sonographic Guide). Assessment of clinical sing such as pain (based on VAS measurement), shoulder range of motion and its function is occurred. Moreover, musculoskeletal sonography is applied by two clinician experts. These (findings are) recorded and compared</i_keyword>
      <i_keyword>The injection for corticosteroid group, however, is applied MethylPrednisolone 40 mg  once or twice within a month based on the Rheumatologist decision.&#13;
At the baseline, after four weeks and also eight weeks after intervention, all the studies including pain, range of motion, function, and Sonographic findings changes are evaluated and compared with the data which is recorded before intervention</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: every 2 weeks up to 8 weeks. Method of measurement: VAS scale.</prim_outcome>
      <prim_outcome>Range of motion. Timepoint: every 2 weeks up to 3 months. Method of measurement: Goniameter.</prim_outcome>
      <prim_outcome>Sonographic finding. Timepoint: at base line and 3 months later. Method of measurement: Sonographic prob.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-07-20</approval_date>
        <contact_name>Tehran University of Medical Sciences</contact_name>
        <contact_address>Ghods street Keshavars Blv Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
